Oppenheimer Holdings Stock News

Enanta Pharmaceuticals (NASDAQ:ENTA) had its target price upped by Oppenheimer from $55.00 to $73.00 in a research report released on Wednesday morning, The Fly reports. The firm currently has a market perform rating on the biotechnology companys stock. A number of other analysts have also weighed in on the stock. JMP Securities increased their price []

XPO Logistics (NYSE:XPO) had its price target cut by Oppenheimer from $108.00 to $96.00 in a research note published on Monday morning, The Fly reports. They currently have an outperform rating on the transportation companys stock. Oppenheimer also issued estimates for XPO Logistics Q4 2021 earnings at $0.96 EPS, FY2021 earnings at $4.18 EPS, Q1 []

XPO Logistics, Inc. (NYSE:XPO) – Analysts at Oppenheimer issued their Q4 2022 earnings per share estimates for shares of XPO Logistics in a research note issued to investors on Sunday, November 21st. Oppenheimer analyst S. Schneeberger expects that the transportation company will post earnings per share of $0.97 for the quarter. Oppenheimer currently has a […]

Semtech Co. (NASDAQ:SMTC) Analysts at Oppenheimer boosted their Q3 2022 earnings per share estimates for Semtech in a research report issued on Monday, November 22nd. Oppenheimer analyst R. Schafer now expects that the semiconductor company will post earnings of $0.52 per share for the quarter, up from their previous forecast of $0.49. Oppenheimer currently []

CNBC Television published this video item, entitled Oppenheimers Read more

PennantPark Floating Rate Capital Ltd. (NASDAQ:PFLT) Equities researchers at Oppenheimer issued their Q1 2023 earnings estimates for PennantPark Floating Rate Capital in a report released on Thursday, November 18th. Oppenheimer analyst M. Penn expects that the asset manager will post earnings per share of $0.28 for the quarter. Oppenheimer also issued estimates for PennantPark []

John Stoltzfus, CIO of Oppenheimer. Oppenheimer Co. Oppenheimer''s John…

CYBIN INC. (CYBN.NE) (OTCMKTS:CYBN) had its target price hoisted by equities researchers at HC Wainwright from $8.00 to $10.00 in a note issued to investors on Monday, The Fly reports. The brokerage currently has a buy rating on the stock. CYBN has been the subject of a number of other reports. Oppenheimer started coverage on []

Semtech (NASDAQ:SMTC) had its target price raised by equities research analysts at Oppenheimer from $85.00 to $100.00 in a research report issued on Monday, The Fly reports. The brokerage presently has an outperform rating on the semiconductor companys stock. Oppenheimers price objective suggests a potential upside of 8.71% from the companys current price. A number []

Gain Therapeutics, Inc. (NASDAQ:GANX) Investment analysts at Oppenheimer reduced their FY2021 EPS estimates for shares of Gain Therapeutics in a note issued to investors on Wednesday, November 17th. Oppenheimer analyst H. Singh now anticipates that the company will earn ($1.60) per share for the year, down from their prior estimate of ($1.30). Oppenheimer has []

Oppenheimer (NYSE: OPY) is one of 53 public companies in the Security brokers & dealers industry, but how does it weigh in compared to its competitors? We will compare Oppenheimer to related businesses based on the strength of its valuation, institutional ownership, earnings, dividends, analyst recommendations, profitability and risk. Volatility and Risk Oppenheimer has a []

Jack in the Box (NASDAQ:JACK) had its price target cut by Oppenheimer from $135.00 to $130.00 in a report released on Thursday, The Fly reports. They currently have an outperform rating on the restaurant operators stock. A number of other research analysts also recently issued reports on JACK. Wells Fargo & Company dropped their price []

Intuit (NASDAQ:INTU) had its price target raised by stock analysts at Oppenheimer from $584.00 to $696.00 in a research report issued to clients and investors on Friday, The Fly reports. The brokerage presently has an outperform rating on the software makers stock. Oppenheimers price objective points to a potential upside of 0.53% from the companys []

Aramark (NYSE:ARMK) Investment analysts at Oppenheimer issued their Q1 2022 EPS estimates for Aramark in a report issued on Tuesday, November 16th. Oppenheimer analyst I. Zaffino anticipates that the company will earn $0.19 per share for the quarter. Oppenheimer also issued estimates for Aramarks Q2 2022 earnings at $0.22 EPS and FY2022 earnings at []